This retrospective study demonstrates a promising biomarker's ability to predict outcomes in high-volume mCSPC, suggesting timely treatment adjustments.
The PSA Kelim Score seems to be a promising and practical prognostic biomarker in high-volume mCSPC. Early PSA decline (Kelim < 1) correlates with better outcomes, regardless of ARPI type. Incorporating it into clinical decision-making may allow for timely treatment adjustments. Prospective validation is needed.
No takes yet. Share an insight, caveat, or question.
Oksuz et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: